Biotechnology

With a novel nasal spray targeting the host, not the virus, RA Capital-backed NorthLinks Bio aims to create a broad-spectrum defense against respiratory threats.

With a fresh $190M, Osanni Bio is pioneering a radical new model for drug discovery—building an ecosystem of specialized spinoffs to accelerate cures.

Right Brain Bio is leveraging Dassault Systèmes' powerful MEDIDATA platform to accelerate a radical new therapy that could reverse Parkinson's pathology.

Veristat isn't just hiring; it's assembling a brain trust to conquer biotech's toughest frontiers. Here's the story behind its strategic talent grab.

An FDA fast-track for a devastating brain disease drug is a beacon of hope for patients and a major validation of Alphabet's long-term biotech strategy.

Amylyx reveals positive initial safety data for its new ALS drug, AMX0114, a critical step as the firm aims to rebuild after the Relyvrio withdrawal.

With a promising drug, fresh cash, and a new board member known for billion-dollar exits, Avalo Therapeutics is signaling a major strategic shift.

A Boston biotech advances a first-in-class antibody into trials, aiming to halt the cellular engine of fibrosis that drives chronic kidney disease.

A biopharma firm's celebrated 20% growth is now alleged to be a mirage, sparking a fraud lawsuit that questions where the line is drawn between ambition and accountability.

With millions suffering from chronic gout, Atom Therapeutics' new drug promises more than relief—it aims to reverse damage. Is this the breakthrough?

The diagnostics firm is launching a monthly webinar series, an unusual move that blends investor relations with direct-to-consumer marketing. Is this the new playbook?

With a sub-$10M market cap and blockbuster data, IMUNON's CEO faces a critical test: convince Wall Street its ovarian cancer drug is the real deal.

After a stunning FDA reversal for its Huntington's drug, uniQure seeks $150M. A look at the high-stakes financing behind a pipeline of hope and risk.

Ottawa's quiet $892K investment in a Vancouver biotech firm is more than a grant; it's a calculated move to secure Canada's food supply from a post-antibiotic crisis.

New 2- and 3-year data shows lebrikizumab sustains skin clearance with less frequent dosing, offering patients flexibility and positioning Eli Lilly for a major market share.

For bladder cancer patients facing bladder removal, a novel therapy from Sweden offers new hope. A US trial expansion targets the most resistant cases.

With a new brand and $1B in state funding, Indiana is unifying its massive bioscience sector to challenge global hubs like Boston. Is 'BioHeartland' the real deal?

A projected 12.4% CAGR signals a boom in hematopoietic stem cell transplantation, but the real story lies in the science poised to overcome timeless hurdles.

Integral Molecular wins another 'Top Workplace' award, but the real story is how its people-first culture is fueling scientific breakthroughs and building a city.

Parexel's new biotech incubator isn't just another funding vehicle. It's a strategic move to embed regulatory expertise at the seed stage, betting that early guidance is more valuable than capital alone.